The Clinical Trials Research Centre is currently recruiting volunteers for clinical trials with the following eye conditions:
- Diabetic Macular Oedema
- Macular Telangiectasia
- Retinal Vein Occlusion
We are also involved in studies for the following eye conditions:
Age-related Macular Degeneration (AMD)
Age-related Macular Degeneration (AMD) is a degenerative disease that affects the central area of the retina called the macula, causing it to deteriorate and in some cases bleed. There are two type of AMD – wet and dry.
The Clinical Trials Research Centre is currently recruiting for patients with newly diagnosed and untreated ‘wet’ (neovascular) AMD and late stage ‘dry’ AMD.
Central Serous Chorioetinopathy (CSCR)
Central serous chorioretinopathy is a retinal condition where there is an accumulation of fluid under the retina. This results in blurred vision or distorted vision.
A corneal transplant involves a surgical procedure to replace the diseased or scarred cornea with a healthy cornea from an organ donor. The aim is to improve vision or to maintain the structural integrity of the eye in cases of injury.
Diabetic Macular Oedema
Diabetic macular oedema is the common cause of vision loss associated with diabetic eye disease (retinopathy). Blood vessels in the retina at the back of the eye leak and cause swelling which leads to blurry vision.
The Clinical Trials Research Centre is currently recruiting for patients with diabetic macular oedema.
Dry eyes occurs when the eye is not able to produce enough tears or maintain the tears on the surface of the eye for long enough to keep the eye comfortable.
Glaucoma is the leading cause of irreversible blindness worldwide. It is an eye condition where there is progressive damage to the optic nerve which, if left untreated, can lead to vision loss and visual field loss.
Inflammation of the cornea, the outermost layer of the eye that covers the pupil and iris which can be caused by infection or injury.
Idiopathic Juxtafoveal Macular Telangiectasia (MacTel).
Idiopathic means ‘of unknown cause’. Juxtafoveal refer to the abnormalities in the blood vessels near, or around, the fovea of the macula. Type 2 MacTel involves widespread dilation and leakage of these vessels. As damage occurs, new blood vessels form within the macula and subsequently break or leak. The result is the formation of scar tissue over the macula and the fovea. This series of events drastically impacts the area of central vision.
A subspecialty in neurological disorders of the eye and visual systems. These eye conditions are usually confined to the optic nerve or the nervous system but may at other times be related to a general medical condition. Symptoms can include double vision, visual loss, eye pain or reduced colour vision.
Eye disorders include: optic neuritis (inflammation of the optic nerve), optic neuropathy (abnormalities or damage to the optic nerve) and giant cell arteritis (GCA).
Retinal detachment is a disorder where the retina separates from the layer of the back of the eye. Detachments may cause symptoms of floaters, flashes of light or a curtain over the field of vision. If left untreated, this can lead to permanent vision loss.
Retinal Vein Occlusion (RVO)
A retinal vein occlusion is a blockage of a vein in the retina at the back of the eye. It can cause a sudden, painless reduction in vision. There are two types of retinal vein occlusion – a branch retinal vein occlusion which affects a section of the retina, or a central retinal vein occlusion where the main retinal vein is blocked, this may result in more severe visual loss.
The Clinical Trials Research Centre is currently recruiting for patients with central retinal vein occlusion.
Uveitis is a condition of inflammation of the middle layer of the eye, which extends from the iris at the front of the eye to the retina and choroid at the back of the eye. Symptoms include red or watery eyes, pain, light sensitivity, and blurred vision. The cause is often unknown but may be due to infection or an autoimmune disease.
The Clinical Trials Research Centre is currently recruiting for patients with macular oedema (swelling of the centre of the back of the eye) due to uveitis and patients who require the addition of a ‘steroid-sparing agent’ to control their uveitis.